

DRUG DISCOVERY & DEVELOPMENT - 2015

Global Scenario - Indian perspective

20-21, November 2015

IL1	<p>Dr Ramesh Panchagnula Vice President & Head : Nektar Therapeutics (India) Pvt. Ltd., Hyderabad Understanding the unknowns of Drug Development</p>
IL2	<p>Prof Javed Iqbal Founder & Chairman : Cosmic Therapeutics, Hyderabad AMP activated Protein Kinase: A Therapeutic target for total Metabolic Control</p>
IL3	<p>Dr Ian Cliffe Vice President & Head : Research Management Daiichi Sankyo India Pharma Private Limited Chemical lead generation in the pharmaceutical industry</p>
IL4	<p>Dr Mukul R Jain Senior Vice President- Pharmacology : Zydus Research Centre, Ahmedabad Saroglitazar: India's answer to global epidemic of diabetic dyslipidemia</p>
IL5	<p>Dr A. K. S. Bhujanga Rao President : Natco Research Centre, Hyderabad Advances in Kinase Inhibitors: A case study of a New Experimental Drug</p>
IL6	<p>Dr Murali Ramachandra Senior Vice President : Aurigene Discovery Technologies Ltd., Bangalore Discovery of Novel Immunomodulating Agents for Cancer Treatment</p>
IL7	<p>Prof Pratipal Singh Professor in Pharmacology : NIPER S.A.S.Nagar Discovery of antimalarial drugs and apicoplast biosynthetic pathways</p>
IL8	<p>Dr Brian W Dymock Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore Discovery of the JAK2/FLT3 Inhibitor Pacritinib and the Creation of Designed Bispecific Molecules Inhibiting Both JAK2 and HDAC at Low Nanomolar Concentrations</p>
IL9	<p>Dr Subramanian Ganesan Senior Investigator, Novartis Healthcare Private Limited Challenges and Opportunities in Predicting first in man dose</p>
IL10	<p>Dr J. B. Gupta Chief Scientific Officer, GVK Biosciences, Hyderabad Translation of animal model's efficacy to clinical trials</p>
IL11	<p>Prof. Subhash Padhye Director, ISTR, Pune Novel strategies targeting cancer stem cells through phytochemicals and their analogs</p>
IL12	<p>Prof (Dr.) Parimal Misra Dr. Reddy's Institute of Life Sciences, Hyderabad Statins: Saints or Satans? A translational approach to understanding why statins cause insulin resistance and type 2 diabetes</p>
IL13	<p>Dr. Sharmista Banerjee University of Hyderabad</p>
IL14	<p>Dr A. K. Chakraborti Professor, NIPER S.A.S.Nagar New Anti-Inflammatory Scaffolds Thorough Sustainable Medicinal Chemistry</p>
IL15	<p>Dr Debnath Bhuniya Director - Discovery Chemistry : Advinus Therapeutics Ltd., Pune Concepts in Drug Discovery: A Case Study with Glucokinase Modulation for T2D</p>
IL16	<p>Dr Muraleedharan K M Department of Chemistry, IIT Chennai Dihydroquinolines as redox modulators with anti-proliferative and anti-bacterial properties</p>